ReviewAIDS research and therapy2016
Gut barrier structure, mucosal immunity and intestinal microbiota in the pathogenesis and treatment of HIV infection.
Review in AIDS research and therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 98 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
98 citing papers in PubMed, 145 citations in OpenAlex.
- Biomarkers of mortality in adults and adolescents with advanced HIV in sub-Saharan Africa.Nature communications · 2024Trial
- Lower Pretreatment Gut Integrity Is Independently Associated With Fat Gain on Antiretroviral Therapy.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2019Trial
- Senescence-associated loss of intestinal α1,2-fucose disrupts a modifiable host-microbiome homeostasis axis in people with HIV.bioRxiv : the preprint server for biology · 2026Article
- Association Between Gut Microbiota and HIV Infection Risk: Insights from Mendelian Randomization and 16S rRNA Amplicon Sequencing.Microorganisms · 2026Article
- Modeling of longitudinal immune profiles reveals distinct immunogenic signatures following five COVID-19 vaccinations among people living with HIV.Patterns (New York, N.Y.) · 2026Article
- Bacterial fecal microbiome composition associated with HIV stage among rural and peri-urban adults living with HIV in Uganda.BMC infectious diseases · 2026Article
- Early Combination Antiretroviral Therapy Initiation During Primary HIV Infection Restricts HIV Reservoirs and Gut-Driven Inflammation but Fails to Rewire the Systemic Cytokine Landscape.Open forum infectious diseases · 2026Article
- Abnormal characteristics of intestinal microenvironment in HIV immunological non-responders.Frontiers in immunology · 2026Review
- Mucosal and systemic immune signatures reveal compartmentalized regulation of gut barrier integrity in virologically suppressed HIV Infection.Frontiers in immunology · 2026Article
- Article
- HIV-Associated Lymphomas: Updates from Pathogenesis to Treatment Strategies.Current HIV research · 2026Review
- Cardiac MRI in Identifying Myopericarditis Mimicking STEMI in a Patient with HIV: A Case Report.The American journal of case reports · 2025Article
- Characterization of the gut microbiota in different immunological responses among PLWH.Scientific reports · 2025Article
- Galectin 9 Levels as a Potential Predictor of Intact HIV Reservoir Decay.The Journal of infectious diseases · 2025Observational
- Gut microbiome composition influences immunologic alterations in the blood and gut of HIV-positive and HIV-negative men who have sex with men.Frontiers in immunology · 2025Article
- HIV and the gut: implications for HIV persistence, immune dysfunction and cure strategies.Frontiers in immunology · 2025Review
- Three-Month cART Initiated During Primary HIV Does Not Correct the Structural, Immune, and Microbial Abnormalities within the Gastrointestinal Tract.Pathogens & immunity · 2025Article
- Insights to the HIV-associated visceral leishmaniasis clinical outcome: lessons learned about immune mediated disorders.Frontiers in immunology · 2025Review
- Matrix Metalloproteinase-9 Signaling Regulates Colon Barrier Integrity in Models of HIV Infection.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2024Article
- The impact of HIV antiretroviral therapy on gut microbiota: the need for well-designed longitudinal studies.Journal of infection in developing countries · 2024Review
38 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Over the past 10 years, extensive work has been carried out in the field of microbial translocation in HIV infection, ranging from studies on its clinical significance to investigations on its pathogenic features. In the present work, we review the most recent findings on this phenomenon, focusing on the predictive role of microbial translocation in HIV-related morbidity and mortality, the mechanisms by which it arises and potential therapeutic approaches. From a clinical perspective, current work has shown that markers of microbial translocation may be useful in predicting clinical events in untreated HIV infection, while conflicting data exist on their role in cART-experienced subjects, possibly due to the inclusion of extremely varied patient populations in cohort studies. Results from studies addressing the pathogenesis of microbial translocation have improved our knowledge of the damage of the gastrointestinal epithelial barrier occurring in HIV infection. However, the extent to which mucosal impairment translates directly to increased gastrointestinal permeability remains an open issue. In this respect, novel work has established a role for IL-17 and IL-22-secreting T cell populations in limiting microbial translocation and systemic T-cell activation/inflammation, thus representing a possible target of immune-therapeutic interventions shown to be promising in the animal model. Further, recent reports have not only confirmed the presence of a dysbiotic intestinal community in the course of HIV infection but have also shown that it may be linked to mucosal damage, microbial translocation and peripheral immune activation. Importantly, technical advances have also shed light on the metabolic activity of gut microbes, highlighting the need for novel therapeutic approaches to correct the function, as well as the composition, of the gastrointestinal microbiota.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.